Survival after fulminant myocarditis induced by immune-checkpoint inhibitors

Annals of Internal Medicine

Volumn 167, Issue 9, 2017, Pages 683-684

  Arangalage, Dimitri ^a,b   Delyon, Julie ^b,c   Lermuzeaux, Mathilde ^a   Ekpe, Kenneth ^c   Ederhy, Stéphane ^c   Pages, Cécile ^c   Lebbé, Céleste ^b,c  

^a BICHAT HOSPITAL   (France)

^b Institut National de la Santeet de la Recherche Me'Dicale Paris   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; GADOLINIUM; IMMUNOGLOBULIN; IPILIMUMAB; LEVOTHYROXINE; METHYLPREDNISOLONE; NIVOLUMAB; TACROLIMUS; THYROTROPIN; TROPONIN I; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ASSISTED CIRCULATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXTRACORPOREAL OXYGENATION; FEMALE; FOLLOW UP; FULMINANT MYOCARDITIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNE RELATED HYPERTHYROIDISM; IMMUNOTHERAPY; INTENSIVE CARE UNIT; LETTER; MYOCARDITIS; NECK CANCER; PLASMA EXCHANGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINUS TACHYCARDIA; ST SEGMENT ELEVATION; SURVIVAL; TRANSTHORACIC ECHOCARDIOGRAPHY; CHEMICALLY INDUCED; HEAD AND NECK TUMOR; MELANOMA;

ADULT; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IPILIMUMAB; MELANOMA; MYOCARDITIS;

EID: 85033784005     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L17-0396     Document Type: Letter

References (5)

1. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558-68. [PMID: 27622997] doi:10.1016/S1470-2045(16)30366-7.
2. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34. [PMID: 26027431] doi:10.1056/NEJMoa1504030.
3. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-55. [PMID: 27806233].
4. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19: 21. [PMID: 28220466] doi:10.1007/s11886-017-0835-0.
5. Ederhy S, Voisin A-L, Champiat S. Myocarditis with immune checkpoint blockade [Letter]. N Engl J Med. 2017;376:290-1. [PMID: 28102662] doi:10.1056/NEJMc1615251.